The Dynamic Use of <i>EGFR</i> Mutation Analysis in Cell-Free DNA as a Follow-Up Biomarker during Different Treatment Lines in Non-Small-Cell Lung Cancer Patients

<div>Longitudinal study of <i>EGFR</i> mutational levels (SQI) during successive treatments.</div>

Disease Markers

fig3

Figure 3

Figure 3: The Dynamic Use of <i>EGFR</i> Mutation Analysis in Cell-Free DNA as a Follow-Up Biomarker during Different Treatment Lines in Non-Small-Cell Lung Cancer Patients 

Figure 3 | The Dynamic Use of EGFR Mutation Analysis in Cell-Free DNA as a Follow-Up Biomarker during Different Treatment Lines in Non-Small-Cell Lung Cancer Patients 